Pacira BioSciences spent nearly a decade owning a pain-relief device that already carried FDA clearance. This week it agreed to sell that device to Zimmer Biomet for up to $140 million, and the terms give the game away: the money is not paying for the technology. The iovera system has worked, and been legal to sell, since 2017. What Zimmer is buying is the one thing a clearance certificate never hands you, which is a commercial engine that actually fits the product. I have watched a lot of founders mistake a regulatory milestone for a business, and that gap is the whole lesson sitting inside this deal.
What Zimmer actually bought
On June 30, Pacira announced it would divest its iovera business to Zimmer Biomet, the orthopedics-device maker, in a deal worth up to $140 million: $70 million up front and another $70 million tied to milestones running through the end of 2031, per the company’s release. Fierce Biotech reported the terms. The transaction is expected to close by the end of September. iovera is a handheld device that delivers controlled doses of cold to a targeted nerve and briefly interrupts the transmission of pain signals, a drug-free option for procedures where a clinician might otherwise reach for an opioid or a nerve block. It was developed by a company called Myoscience, cleared by the FDA in 2017, and picked up by Pacira when it acquired Myoscience in 2019.
A cleared device is not a business
So why does a nine-year-old cleared product change hands for that kind of money now? Read Pacira’s own explanation. Its chief executive said the sale advances the company’s shift toward being a biopharmaceutical business, and that Zimmer’s established expertise commercializing medical devices, plus its reach, could unlock the full potential of iovera. Put back into plain terms: iovera sat inside a company built to sell injectable drugs like Exparel and Zilretta through a pharmaceutical sales motion, and a handheld capital device sold into orthopedic and surgical suites is a different animal. The clearance was never the constraint. The commercial fit was.
I have lived the version of this where the technology was not just cleared but dominant, and still was not a business. At Ascend Communications in the 1990s I came in as a software person to a hardware company, and inside our access concentrators sat thirty million lines of code that were quietly running roughly ninety percent of the world’s dial-up internet. I did not write a line of it. The engineering teams did. What that code lacked was a name and a commercial identity, so it lived as a feature nobody could point at until we branded it as an operating system, called it TAOS, and sold it as one. The engineering was already excellent, and the thing that moved the needle was the decision to treat it as a product with its own identity. iovera is that lesson in a different industry: a real device with a real clearance that landed in the wrong commercial home.
What this means if you are about to clear a device
If you are a hard-tech founder anywhere near a De Novo, a 510(k), or a CE mark, this deal is worth sitting with. Clearance answers one question honestly, which is whether it is safe and legal to put your device in front of customers. It says nothing about whether your company has the sales motion, the distribution channel, and the reorder relationships to actually move it. Those are separate builds, and the second one is usually harder and slower than the regulatory one. A cleared device in a company whose commercial instincts do not match it can sit for years, which is roughly what happened here before Zimmer arrived with a channel that fits. When you map your plan, do not let the clearance date quietly become your go-to-market date. They answer different questions, and only one of them pays the bills.
Dave’s take
The trap I watch founders fall into is treating a regulatory approval as the finish line, when it is closer to a permit than a business. Pacira held a working, cleared device for years and is now taking seventy million dollars up front because someone else owns the channel that fits it. Build the commercial engine with the same seriousness you bring to the submission, or you may end up selling the fruit of your work to whoever did.
I’m here to help you scale.
Work With DavePrefer a smaller first step? Book a $500 one-hour consultation →
Dave Saunders is the founder of Base Reality Group and a Fractional CPO for hard-tech founders. He was a founder and operator at Galen Robotics, where the surgical-robotics platform earned FDA De Novo authorization in 2023, and he managed a 35-patent portfolio licensed from Johns Hopkins. He wrote Founders Who Finish and publishes The Build. More about Dave →